|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brown LM, Devesa SS and Chow WH: Incidence
of adenocarcinoma of the esophagus among white Americans by sex,
stage, and age. J Natl Cancer Inst. 100:1184–1187. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Law S and Wong J: The current management
of esophageal cancer. Adv Surg. 41:93–119. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Headrick JR, Nichols FC III, Miller DL,
Allen MS, Trastek VF, Deschamps C, Schleck CD, Thompson AM and
Pairolero PC: High-grade esophageal dysplasia: Long-term survival
and quality of life after esophagectomy. Ann Thorac Surg.
73:1697–1703. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin DC, Hao JJ, Nagata Y, Xu L, Shang L,
Meng X, Sato Y, Okuno Y, Varela AM, Ding LW, et al: Genomic and
molecular characterization of esophageal squamous cell carcinoma.
Nat Genet. 46:467–473. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cancer Genome Atlas Research Network:
Analysis Working Group: Asan University; BC Cancer Agency; Brigham
and Women's Hospital; Broad Institute; Brown University; Case
Western Reserve University; Dana-Farber Cancer Institute; Duke
University; Greater Poland Cancer Centre, et al, . Integrated
genomic characterization of oesophageal carcinoma. Nature.
541:169–175. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee RC, Feinbaum RL and Ambros V: The C.
Elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ruvkun G: Molecular biology. Glimpses of a
tiny RNA world. Science. 294:797–799. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takeshita N, Hoshino I, Mori M, Akutsu Y,
Hanari N, Yoneyama Y, Ikeda N, Isozaki Y, Maruyama T, Akanuma N, et
al: Serum microRNA expression profile: miR-1246 as a novel
diagnostic and prognostic biomarker for oesophageal squamous cell
carcinoma. Br J Cancer. 108:644–652. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wei C, Li Y, Huang K, Li G and He M:
Exosomal miR-1246 in body fluids is a potential biomarker for
gastrointestinal cancer. Biomark Med. 12:1185–1196. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ni S, Weng W, Xu M, Wang Q, Tan C, Sun H,
Wang L, Huang D, Du X and Sheng W: miR-106b-5p inhibits the
invasion and metastasis of colorectal cancer by targeting CTSA.
OncoTargets Ther. 11:3835–3845. 2018. View Article : Google Scholar
|
|
14
|
Li N, Miao Y, Shan Y, Liu B, Li Y, Zhao L
and Jia L: miR-106b and miR-93 regulate cell progression by
suppression of PTEN via PI3K/Akt pathway in breast cancer. Cell
Death Dis. 8:e27962017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen S, Chen X, Xiu YL, Sun KX and Zhao Y:
Inhibition of ovarian epithelial carcinoma tumorigenesis and
progression by microRNA 106b mediated through the RhoC pathway.
PLoS One. 10:e01257142015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen G, Jia H, Tai Q, Li Y and Chen D:
miR-106b downregulates adenomatous polyposis coli and promotes cell
proliferation in human hepatocellular carcinoma. Carcinogenesis.
34:211–219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang A, Hao J, Wang K, Huang Q, Yu K,
Kang C, Wang G, Jia Z, Han L and Pu P: Down-regulation of miR-106b
suppresses the growth of human glioma cells. J Neurooncol.
112:179–189. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu Y, Wang K, Gao W, Zhang C, Huang F, Wen
S and Wang B: MicroRNA-106b regulates the tumor suppressor RUNX3 in
laryngeal carcinoma cells. FEBS Lett. 587:3166–3174. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu F, Gong J, Huang W, Wang Z, Wang M,
Yang J, Wu C, Wu Z and Han B: MicroRNA-106b-5p boosts glioma
tumorigensis by targeting multiple tumor suppressor genes.
Oncogene. 33:4813–4822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Prasad R and Katiyar SK: Down-regulation
of miRNA-106b inhibits growth of melanoma cells by promoting
G1-phase cell cycle arrest and reactivation of p21/WAF1/Cip1
protein. Oncotarget. 5:10636–10649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhuang M, Zhao S, Jiang Z, Wang S, Sun P,
Quan J, Yan D and Wang X: MALAT1 sponges miR-106b-5p to promote the
invasion and metastasis of colorectal cancer via SLAIN2 enhanced
microtubules mobility. EBioMedicine. 41:286–298. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hoshino I and Matsubara H: MicroRNAs in
cancer diagnosis and therapy: From bench to bedside. Surg Today.
43:467–478. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hermeking H: MicroRNAs in the p53 network:
Micromanagement of tumour suppression. Nat Rev Cancer. 12:613–626.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schwarzenbach H, Nishida N, Calin GA and
Pantel K: Clinical relevance of circulating cell-free microRNAs in
cancer. Nat Rev Clin Oncol. 11:145–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Skog J, Würdinger T, van Rijn S, Meijer
DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky
AM and Breakefield XO: Glioblastoma microvesicles transport RNA and
proteins that promote tumour growth and provide diagnostic
biomarkers. Nat Cell Biol. 10:1470–1476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Khoury S and Tran N: Circulating
microRNAs: Potential biomarkers for common malignancies. Biomark
Med. 9:131–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kumar S, Sharawat SK, Ali A, Gaur V, Malik
PS, Kumar S, Mohan A and Guleria R: Identification of
differentially expressed circulating serum microRNA for the
diagnosis and prognosis of Indian non-small cell lung cancer
patients. Curr Probl Cancer. 44:1005402020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoshida K, Yokoi A, Kagawa T, Oda S,
Hattori S, Tamauchi S, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F,
et al: Unique miRNA profiling of squamous cell carcinoma arising
from ovarian mature teratoma: Comprehensive miRNA sequence analysis
of its molecular background. Carcinogenesis. 40:1435–1444.
2019.PubMed/NCBI
|
|
31
|
Chuma M, Toyoda H, Matsuzaki J, Saito Y,
Kumada T, Tada T, Kaneoka Y, Maeda A, Yokoo H, Ogawa K, et al:
Circulating microRNA-1246 as a possible biomarker for early tumor
recurrence of hepatocellular carcinoma. Hepatol Res. 49:810–822.
2019.PubMed/NCBI
|
|
32
|
Shi Y, Wang Z, Zhu X, Chen L, Ma Y, Wang
J, Yang X and Liu Z: Exosomal miR-1246 in serum as a potential
biomarker for early diagnosis of gastric cancer. Int J Clin Oncol.
25:89–99. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moshiri F, Salvi A, Gramantieri L,
Sangiovanni A, Guerriero P, De Petro G, Bassi C, Lupini L, Sattari
A, Cheung D, et al: Circulating miR-106b-3p, miR-101-3p and
miR-1246 as diagnostic biomarkers of hepatocellular carcinoma.
Oncotarget. 9:15350–15364. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang F, Xiong H, Duan L, Li Q, Li X and
Zhou Y: miR-1246 promotes metastasis and Invasion of A549 cells by
targeting GSK-3β-mediated Wnt/β-catenin pathway. Cancer Res Treat.
51:1420–1429. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu R, Li H, Wu S, Qu J, Yuan H, Zhou Y and
Lu Q: MicroRNA-1246 regulates the radio-sensitizing effect of
curcumin in bladder cancer cells via activating P53. Int Urol
Nephrol. 51:1771–1779. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen J, Yao D, Zhao S, He C, Ding N, Li L
and Long F: miR-1246 promotes SiHa cervical cancer cell
proliferation, invasion, and migration through suppression of its
target gene thrombospondin 2. Arch Gynecol Obstet. 290:725–732.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Du P, Lai YH, Yao DS, Chen JY and Ding N:
Downregulation of microRNA-1246 inhibits tumor growth and promotes
apoptosis of cervical cancer cells by targeting thrombospondin-2.
Oncol Lett. 18:2491–2499. 2019.PubMed/NCBI
|
|
38
|
Cai K, Wang Y and Bao X: miR-106b promotes
cell proliferation via targeting RB in laryngeal carcinoma. J Exp
Clin Cancer Res. 30:732011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mehlich D, Garbicz F and Włodarski PK: The
emerging roles of the polycistronic miR-106b-25 cluster in cancer -
A comprehensive review. Biomed Pharmacother. 107:1183–1195. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tamilzhalagan S, Rathinam D and Ganesan K:
Amplified 7q21-22 gene MCM7 and its intronic miR-25 suppress COL1A2
associated genes to sustain intestinal gastric cancer features. Mol
Carcinog. 56:1590–1602. 2017. View Article : Google Scholar : PubMed/NCBI
|
